The American Society of Clinical Oncology (ASCO) is now seeking feedback on two draft guideline updates for ovarian cancer and immune-related adverse effects. Individuals interested in providing their comments must agree to a confidentially agreement before they can view the guideline draft for Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Update and Management of Immune-Related Adverse Effects Clinical Practice Guideline Update (Part 1).
Click here to view the confidentiality agreement for the ovarian cancer guideline update.
Click here to view the confidentiality agreement for the immune-related adverse effects guideline update.
The open comment window closes on Wednesday, June 2, at 11:59 PM EST. Another ASCO open comment opportunity for advanced biliary tract cancer is also ongoing, through Friday, May 22, at 11:59 PM EST.